Efficacy and safety of hydroxyurea in patients with essential thrombocythemia

Pathologie-biologie
Guido Finazzi, Tiziano Barbui

Abstract

Hydroxy-urea has emerged as the treatment of choice in patients with essential thrombocythemia and an high risk of thrombosis because of its efficacy and only rare acute toxicity. However, there is some concern regarding the potential role of this drug in enhancing the risk of leukemic transformation. This risk suggests not to use hydroxyurea in young patients at low-risk for thrombosis. In these cases, major or fatal vascular occlusive complications are rare, and no data are available on the effectiveness of HU in reducing this rate. Sequential multiple chemotherapy, such busulphan followed by HU, should be avoided in any case because of the high risk of secondary leukemias.

Citations

Jan 23, 2002·Pharmacoepidemiology and Drug Safety
Dec 26, 2006·International Journal of Hematology·Yasuhiro TanakaTakayuki Takahashi
Sep 15, 2015·Expert Review of Hematology·María Luisa AnteloJose María Raya
Mar 25, 2010·British Journal of Haematology·Claire N HarrisonUNKNOWN British Committee for Standards in Haematology
Dec 12, 2002·Hematology·Apostolia-Maria Tsimberidou, Francis J Giles
Aug 27, 2005·La Revue de médecine interne·R CostelloG Sébahoun
Mar 10, 2005·Leukemia Research·Steven M FruchtmanUNKNOWN Anagrelide Study Group
Sep 1, 2016·World Journal of Clinical Oncology·Rajesh ShresthaVijaya Raj Bhatt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.